MMV688533

DRUG2 trials

Sponsors

Medicines for Malaria Venture

Conditions

Malaria

Phase 1

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

CompletedNCT04323306

Medicines for Malaria VentureMalaria

Start: 2020-08-12End: 2022-09-27Updated: 2024-10-17

MMV533 Plasmodium Falciparum Volunteer Infection Study

CompletedNCT05205941

Medicines for Malaria VentureMalaria

Start: 2022-03-30End: 2022-09-02Updated: 2024-12-02

Related Papers

Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study.

2024-12-185 citations